A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

Asociación Española de Urología [Internet]. [Accessed 30 September 2022]; Available in: https://www.aeu.es/libros.aspx. González del Alba, 2021, SEOM clinical guidelines for the treatment of advanced prostate cancer (2020), Clin Transl Oncol, 23, 969, 10.1007/s12094-021-02561-5 Parker, 2020, Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 31, 1119, 10.1016/j.annonc.2020.06.011 Virgo, 2021, Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update, J Clin Oncol, 39, 1274, 10.1200/JCO.20.03256 EAU Guidelines on Prostate Cancer - Uroweb [Internet]. Uroweb - Eur. Assoc. Urol. [Accessed 22 June 2022]. Available in: https://uroweb.org/guidelines/prostate-cancer. Lowrance, 2021, Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I, J Urol, 205, 14, 10.1097/JU.0000000000001375 AEMPS. Darolutamida. Ficha técnica [Internet]. [Accessed 22 June 2022]. Available in: https://cima.aemps.es/cima/publico/lista.html. Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115 Feyerabend, 2018, Survival benefit, disease progression and qualiT.y-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis, Eur J Cancer 1990, 103, 78 Marchioni, 2020, New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis, J Urol, 203, 751, 10.1097/JU.0000000000000636 Napoli, 2022, A systematic review and a meta-analysis of randomized controlled trials’ control groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Curr Oncol Rep, 24, 1633, 10.1007/s11912-022-01323-y Sathianathen, 2020, Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis, Eur Urol, 77, 365, 10.1016/j.eururo.2019.09.004 Wallis, 2018, Comparison of Abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis, Eur Urol, 73, 834, 10.1016/j.eururo.2017.10.002 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2023 — September 16, 2022. [Internet]. NCCN [Accessed 19 October 2022]. Available in: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. AEMPS. Docetaxel. Ficha técnica. [Internet]. [Accessed 22 June 2022]. Available in: https://cima.aemps.es/cima/publico/lista.html. Baston, 2020, Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data, Curr Opin Urol, 30, 576, 10.1097/MOU.0000000000000778 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet Lond Engl, 387, 1163, 10.1016/S0140-6736(15)01037-5 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0 Gravis, 2016, Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005 AEMPS. Abiraterona. Ficha técnica. [Internet]. [Accessed 22 June 2022]. Available in: https://cima.aemps.es/cima/publico/lista.html. Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 James, 2022, Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476), Int J Cancer, 151, 422, 10.1002/ijc.34018 AEMPS. Apalutamida. Ficha técnica. [Internet]. [Accessed 22 June 2022]. Available in: https://cima.aemps.es/cima/publico/lista.html. Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Chi, 2021, Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study, J Clin Oncol, 39, 2294, 10.1200/JCO.20.03488 AEMPS. Enzalutamida. Ficha técnica. [Internet]. [Accessed 22 June 2022]. Available in: https://cima.aemps.es/cima/publico/lista.html. Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835 Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Armstrong, 2022, Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 40, 1616, 10.1200/JCO.22.00193 Yanagisawa, 2022, Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur Urol, 82, 584, 10.1016/j.eururo.2022.08.002 Fizazi, 2022, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design, Lancet, 399, 1695, 10.1016/S0140-6736(22)00367-1 Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Moreno AJC. Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients. [Internet]. clinicaltrials.gov; 2022 [Accessed 20 November 2022]. Available in: https://clinicaltrials.gov/ct2/show/NCT05209243. Tsao, 2020, Factors to guide treatment selection for hormone-sensitive metastatic prostate cancer, Cancer J Sudbury Mass, 26, 76, 10.1097/PPO.0000000000000423 Elmehrath, 2021, Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2021.19568 Challa, 2021, Cardiovascular toxicities of androgen deprivation therapy, Curr Treat Options Oncol, 22, 47, 10.1007/s11864-021-00846-z Keating, 2022, Cardiovascular and metabolic diagnoses associated with novel hormonal agents for prostate cancer in nontrial populations, JNCI J Natl Cancer Inst, 114, 1057, 10.1093/jnci/djac084 Muniyan, 2020, Cardiovascular risks and toxicity - the Achilles heel of androgen deprivation therapy in prostate cancer patients, Biochim Biophys Acta Rev Cancer, 1874, 10.1016/j.bbcan.2020.188383 Iacovelli, 2018, The cardiovascular toxicity of Abiraterone and enzalutamide in prostate cancer, Clin Genitourin Cancer, 16, e645, 10.1016/j.clgc.2017.12.007 Moreira, 2017, Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials, Oncotarget, 8, 84572, 10.18632/oncotarget.20028 Zhu, 2018, Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis, Expert Rev Anticancer Ther, 18, 193, 10.1080/14737140.2018.1419871 Cone, 2021, Cardiovascular toxicities associated with abiraterone compared to enzalutamide–a pharmacovigilance study, EClinicalMedicine, 36, 10.1016/j.eclinm.2021.100887 Kulkarni, 2021, Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients, ESMO Open, 6, 10.1016/j.esmoop.2021.100261 Hu, 2022, Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data, Clin Genitourin Cancer, 20, 17, 10.1016/j.clgc.2021.08.009 George, 2021, Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden, Acta Oncol, 60, 459, 10.1080/0284186X.2021.1885058 Lu-Yao, 2020, Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities, Eur Urol, 77, 158, 10.1016/j.eururo.2019.07.031 Casado, 2022, Multidisciplinary consensus on the prevention and treatment of osteoporosis and fragility fractures in patients with prostate cancer receiving androgen-deprivation therapy, World J Mens Health, 40, 74, 10.5534/wjmh.210061 Gómez-Aparicio, 2022, Bone health and therapeutic agents in advanced prostate cancer, Front Biosci-Landmark, 27, 34, 10.31083/j.fbl2701034 Buckley, 2017, 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Rheumatol, 69, 1521, 10.1002/art.40137 Yasir Naranjo Hernández, 2019, Recommendations by the Spanish Society of Rheumatology on Osteoporosis, Reumatol Clin (Engl Ed), 15, 188, 10.1016/j.reuma.2018.09.004 Tripathi, 1999, Corticosteroids and glaucoma risk, Drugs Aging, 15, 439, 10.2165/00002512-199915060-00004 Tohi, 2022, Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium, Int J Clin Oncol, 27, 1348, 10.1007/s10147-022-02183-z Pan, 2022, Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor Apalutamide, J Urol, 207, 1010, 10.1097/JU.0000000000002425 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546 Slovin, 2018, Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study, JAMA Oncol, 4, 702, 10.1001/jamaoncol.2017.3361 Zurth, 2019, Higher blood–brain barrier penetration of [ 14 C]apalutamide and [ 14 C]enzalutamide compared to [ 14 C]darolutamide in rats using whole-body autoradiography, J Clin Oncol, 37, 156, 10.1200/JCO.2019.37.7_suppl.156 Hebenstreit, 2020, Drug-drug interactions in prostate cancer treatment, Clin Genitourin Cancer, 18, e71, 10.1016/j.clgc.2019.05.016 Vicente-Valor, 2021, Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice, Expert Opin Drug Metab Toxicol, 17, 1467, 10.1080/17425255.2021.2027908 AEMPS. Ficha técnica enzalutamida. [Internet]. [Accessed 14 June 2020]. Available in: https://cima.aemps.es/cima/pdfs/ft/113846002/FT_113846002.pdf. AEMPS. Ficha técnica apalutamida [Internet]. [Accessed 14 June 2020]. Available in: https://cima.aemps.es/cima/pdfs/es/ft/1181342001/FT_1181342001.pdf. AEMPS. Ficha técnica darolutamida. [Internet]. [Accessed 14 June 2020]. Available in: https://cima.aemps.es/cima/pdfs/p/1201432001/P_1201432001.pdf. Esperanza de vida a distintas edades. Brecha de género. España. 2010 y 2020. [Internet]. INE [Accessed 22 November 2020]. Available in: https://www.ine.es/jaxi/Datos.htm?path=/t00/mujeres_hombres/tablas_1/l0/&file=d01005.px#!tabs-tabla%20. Life expectancy by age and sex - Products Datasets - Eurostat [Internet]. [Accessed 22 November 2020]. Available in: https://ec.europa.eu/eurostat/web/products-datasets/-/demo_mlexpec%20.